Table 1 Influential clinical trials and studies in CAR-T therapy
From: Biomarkers in individualized management of chimeric antigen receptor T cell therapy
NO | Institution | NCT | Author | Year | Journal | No.pts | Condition | Target | CD* | Dose | LD* |
|---|---|---|---|---|---|---|---|---|---|---|---|
13 | Upeen & CHOP | NCT01626495 | Grupp | 2013 | N Engl J Med | 2 | B-ALL | CD19 | 4-1BB | 1.4 × 106 - 1.2 × 107/Kg | N/A |
Fitzgerald | 2016 | Crit Care Med | 39 | B-ALL | |||||||
Gofshteyn | 2018 | Ann Neurol | 51 | ALL | |||||||
NCT02435849 (ELIANA) | Maude | 2018 | N Engl J Med | 75 | B-ALL | CD19 | 4-1BB | 0.2 × 106 - 5.4 × 106/Kg | FC* | ||
Laetsch | 2019 | Lancet Oncol | 58 | ||||||||
NCT02445248 (JULIET) | Schuster | 2019 | N Engl J Med | 93 | DLBCL | CD19 | 4-1BB | N/A | N/A | ||
Bishop | 2019 | Blood Adv | 7 | ||||||||
NCT01029366 | Porter | 2015 | Sci Transl Med | 14 | CLL | CD19 | 4-1BB | 0.142 × 108–11.3 × 108 | Flu*/Cy*/Bendamustine/Pentostatin | ||
NCT02030834 | Schuster | 2017 | N Engl J Med | 28 | DLBCL | CD19 | 4-1BB | 1–5 × 108 | N/A | ||
NCT01626495 NCT01029366 | Maude | 2014 | N Engl J Med | 51 | see in NCT01626495 & NCT01029366 | ||||||
NCT02030847** NCT01626495 NCT01029366 | Teachey | 2016 | Cancer Discov | 51 | ALL | CD19 | 4-1BB | 1.0 × 107 - 5.0 × 108 | N/A | ||
NCT01747486** NCT01029366 | van Bruggen | 2019 | Blood | 27 | CLL | CD19 | 4-1BB | 1.0 × 107 - 5.0 × 108 | N/A | ||
NCT02640209** NCT01747486 NCT01029366 | Fraietta | 2018 | Nat Med | 41 | CLL | CD19 | 4-1BB | 1.0 × 108 - 5.0 × 108 | N/A | ||
8 | FHCRC | NCT01865617 | Turtle | 2016 | J Clin Invest | 30 | B-ALL | CD19 | 4-1BB | 2 × 106/Kg | FC |
2016 | Sci Transl Med | 32 | NHL | ||||||||
2017 | J Clin Oncol | 24 | CLL | ||||||||
Gust | 2017 | Cancer Discov | 133 | B-ALL & NHL & CLL | |||||||
Hay | 2017 | Blood | 133 | B-ALL & NHL & CLL | |||||||
2019 | Blood | 53 | B-ALL | ||||||||
Hirayama | 2019 | Blood | 21 | NHL | |||||||
2019 | Blood | 65 | NHL | ||||||||
7 | NCI | NCT00924326 | Kochenderfer | 2017 | J Clin Oncol | 22 | NHL&CLL | CD19 | CD28 | 1.0 × 106–6.0 × 106/kg | FC |
2015 | J Clin Oncol | 15 | NHL&CLL | ||||||||
Rossi | 2018 | Blood | 22 | NHL | |||||||
NCT01593696 | Lee | 2015 | Lancet | 21 | ALL&NHL | CD19 | CD28 | 1.0 × 106 or 3.0 × 106/kg | FC | ||
NCT02215967 | Ali | 2016 | Blood | 12 | MM | BCMA | CD28 | 9.0 × 106/kg | FC | ||
Brudno | 2018 | J Clin Oncol | 16 | ||||||||
NCT02315612 | Fry | 2018 | Nat Med | 15 | B-ALL | CD19 & CD22 | 4-1BB | ≥1 × 106/Kg | FC | ||
5 | MSKCC | NCT01044069 | Brentjens | 2013 | Sci Transl Med | 5 | B-ALL | CD19 | CD28 | 1.0 × 106–3.0 × 106/kg | FC/Cy/ Cy + clofarabine |
Davila | 2014 | Sci Transl Med | 16 | ||||||||
Park | 2018 | N Engl J Med | 53 | ||||||||
2018 | Clin Infect Dis | 53 | |||||||||
Santomasso | 2018 | Cancer Discov | 53 | ||||||||
3 | SCRI | NCT02028455 | Gardner | 2017 | Blood | 45 | B-ALL | CD19 | CD28 | 0.5 × 106–10.0 × 106/kg | Flu/Cy |
2016 | Blood | 7 | |||||||||
Finney | 2019 | J Clin Invest | 43 | ||||||||
3 | Moffitt Cancer Center | NCT02348216 (ZUMA-1) | Locke | 2017 | Mol Ther | 7 | NHL | CD19 | CD28 | 2 × 106/Kg | FC |
2019 | Lancet Oncol | 108 | |||||||||
M.D.Anderson Cancer Center | Neelapu | 2017 | N Engl J Med | 101 | |||||||